The efficacy of PDE5 inhibitors in diabetic patients.

Keyphrases

• Phosphodiesterase Type 5 Inhibitors 100%
• PDE5 Inhibitors 100%
• Diabetic Patients 100%
• Diabetes 40%
• Human Studies 40%
• Cardiovascular Disease 40%
• Human Trials 40%
• Vascular Complications 40%
• Diabetic 20%
• Randomized Controlled Trial 20%
• Clinical Trials 20%
• Insulin Resistance 20%
• Animal Data 20%
• Clinical Outcomes 20%
• Cardiovascular Mortality 20%
• Neuropathic Pain 20%
• Oxidative Stress 20%
• β-cell Function 20%
• Therapeutic Potential 20%
• Erectile Dysfunction 20%
• Specific Interest 20%
• Patients with Diabetes Mellitus 20%
• Established Cardiovascular Disease 20%
• Metabolic Disorders 20%
• Sensory Function 20%
• Improved Wound Healing 20%
• Diabetic Nephropathy 20%
• Diabetic Neuropathy 20%
• Metabolic Dysregulation 20%
• Pulmonary Hypertension 20%
• Pleiotropic Effects 20%
• Albuminuria 20%

Medicine and Dentistry

• Phosphodiesterase V Inhibitor 100%
• Diabetes Mellitus 100%
• Cardiovascular Disease 50%
• Diabetes 33%
• Human Study 33%
• Phosphodiesterase V 33%
• Randomized Controlled Trial 16%
• Drug Therapy 16%
• Clinical Trial 16%
• Cell Function 16%
• Insulin Resistance 16%
• Patient with Diabetes 16%
• Erectile Dysfunction 16%
• Oxidative Stress 16%
• Wound Healing 16%
• Water-Electrolyte Imbalance 16%
• Beta Cell 16%
• Cardiovascular Mortality 16%
• Diabetic Nephropathy 16%
• Diabetic Neuropathy 16%
• Pleiotropy 16%
• Pulmonary Hypertension 16%
• Albuminuria 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Diabetes Mellitus 100%
• Phosphodiesterase V Inhibitor 100%
• Cardiovascular Disease 50%
• Human Study 33%
• Phosphodiesterase V 33%
• Preclinical Study 33%
• Randomized Controlled Trial 16%
• Clinical Trial 16%
• Insulin Resistance 16%
• Cardiovascular Mortality 16%
• Metabolic Disorder 16%
• Wound Healing 16%
• Erectile Dysfunction 16%
• Pulmonary Hypertension 16%
• Diabetic Neuropathy 16%
• Diabetic Nephropathy 16%
• Albuminuria 16%